Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Cytokinetics Inc (CYTK)  
$49.44 1.69 (3.31%) as of 4:30 Mon 9/15


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 144,135,000
Market Cap: 7.13(B)
Last Volume: 8,264,325 Avg Vol: 8,200,260
52 Week Range: $29.84 - $58.62
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Biotechnology

Member Indexes:
    NASDAQ BIOTECHNOLOGY     NASDAQ COMPOSITE
    NASDAQ NNM COMPOSITE

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  1083
Guru Rank Value     : 0
Guru Occurances    : 2

 

            6 Months   1 Year   2 Year  
 
Company Profile   Cytokinetics is a biopharmaceutical company focused on discovering, developing and commercializing muscle activators and muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. Co.'s clinical-stage drug candidates are: Omecamtiv mecarbil, which is being evaluated for the potential treatment of heart failure; Reldesemtiv, which is being evaluated for treatment in patients with amyotrophic lateral sclerosis; Aficamten, which is an oral, small molecule cardiac myosin inhibitor being evaluated in patients with symptomatic, obstructive hypertrophic cardiomyopathy; and CK-3772271, its second cardiac myosin inhibitor.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 0
Total Buy Value $0 $0 $0 $0
Total People Bought 0 0 0 0
Total Buy Transactions 0 0 0 0
Total Shares Sold 50,906 207,895 398,527 890,302
Total Sell Value $2,048,251 $8,329,014 $17,463,521 $46,788,596
Total People Sold 4 8 8 10
Total Sell Transactions 14 38 68 116
End Date 2025-06-15 2025-03-14 2024-09-13 2023-09-14

   
Records found: 912
  Page 1 of 37  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Blum Robert I President & CEO   •       •      –    2025-09-15 4 S $49.77 $248,850 D/D (5,000) 373,108     -
   Malik Fady Ibraham EVP Research & Development   •       •      –    2025-09-09 4 S $51.29 $102,580 D/D (2,000) 140,610 1%     
   Malik Fady Ibraham EVP Research & Development   •       •      –    2025-09-09 4 OE $10.60 $21,200 D/D 2,000 142,610     -
   Blum Robert I President & CEO   •       •      –    2025-09-02 4 S $48.76 $243,800 D/D (5,000) 378,108 -3%     
   Harrington Robert Arthur Director   •       •      –    2025-09-02 4 S $48.67 $104,641 D/D (2,150) 20,493 -3%     
   Kaye Edward M. Md Director   •       •      –    2025-09-02 4 S $50.00 $337,800 D/D (6,756) 23,230 -3%     
   Malik Fady Ibraham EVP Research & Development   •       •      –    2025-08-19 4 S $38.31 $76,620 D/D (2,000) 140,610 -35%     
   Malik Fady Ibraham EVP Research & Development   •       •      –    2025-08-19 4 OE $10.60 $21,200 D/D 2,000 142,610     -
   Blum Robert I President & CEO   •       •      –    2025-08-15 4 S $38.42 $192,100 D/D (5,000) 383,108 -32%     
   Malik Fady Ibraham EVP Research & Development   •       •      –    2025-08-05 4 S $36.34 $72,680 D/D (2,000) 140,610 -41%     
   Malik Fady Ibraham EVP Research & Development   •       •      –    2025-08-05 4 OE $10.60 $21,200 D/D 2,000 142,610     -
   Blum Robert I President & CEO   •       •      –    2025-07-29 4 S $36.45 $182,250 D/D (5,000) 388,108 -42%     
   Malik Fady Ibraham EVP Research & Development   •       •      –    2025-07-22 4 S $37.47 $74,940 D/D (2,000) 140,610 -36%     
   Malik Fady Ibraham EVP Research & Development   •       •      –    2025-07-22 4 OE $10.60 $21,200 D/D 2,000 142,610     -
   Kaye Edward M. Md Director   •       •      –    2025-07-15 4 A $38.01 $12,467 D/D 328 29,986     -
   Henderson John T Director   •       •      –    2025-07-15 4 A $38.01 $21,248 D/D 559 74,240     -
   Harrington Robert Arthur Director   •       •      –    2025-07-15 4 A $38.01 $12,467 D/D 328 22,643     -
   Wysenski Nancy Director   •       •      –    2025-07-15 4 A $38.01 $6,234 D/D 164 30,774     -
   Wierenga Wendall D Director   •       •      –    2025-07-15 4 A $38.01 $6,234 D/D 164 32,345     -
   Blum Robert I President & CEO   •       •      –    2025-07-14 4 S $38.15 $190,750 D/D (5,000) 393,108 -33%     
   Malik Fady Ibraham EVP Research & Development   •       •      –    2025-07-08 4 S $33.76 $67,520 D/D (2,000) 140,610 -49%     
   Malik Fady Ibraham EVP Research & Development   •       •      –    2025-07-08 4 OE $10.60 $21,200 D/D 2,000 142,610     -
   Blum Robert I President & CEO   •       •      –    2025-07-01 4 S $33.55 $167,750 D/D (5,000) 398,108 -52%     
   Malik Fady Ibraham EVP Research & Development   •       •      –    2025-06-17 4 S $32.91 $65,820 D/D (2,000) 140,610 -57%     
   Malik Fady Ibraham EVP Research & Development   •       •      –    2025-06-17 4 OE $10.60 $21,200 D/D 2,000 142,610     -
  912 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 1 of 37
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2025 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us